CL2018000142A1 - Métodos para el tratamiento de trastornos de desarrollo con gaboxadol. - Google Patents

Métodos para el tratamiento de trastornos de desarrollo con gaboxadol.

Info

Publication number
CL2018000142A1
CL2018000142A1 CL2018000142A CL2018000142A CL2018000142A1 CL 2018000142 A1 CL2018000142 A1 CL 2018000142A1 CL 2018000142 A CL2018000142 A CL 2018000142A CL 2018000142 A CL2018000142 A CL 2018000142A CL 2018000142 A1 CL2018000142 A1 CL 2018000142A1
Authority
CL
Chile
Prior art keywords
gaboxadol
treatment
syndrome
developmental disorders
methods
Prior art date
Application number
CL2018000142A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CL2018000142A1 publication Critical patent/CL2018000142A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>Uso de 0,05 mg a 30 mg de gaboxadol o su sal farmacéuticamente aceptable para el tratamiento de trastornos del desarrollo tal como síndrome de Angelman, síndrome de X frágil, síndrome de temblor/ataxia relacionado con X frágil, trastorno de espectro autista, autismo, Asperger, trastorno general de desarrollo, trastorno disociativo de la infancia y síndrome de Rett. </p>
CL2018000142A 2015-07-17 2018-01-17 Métodos para el tratamiento de trastornos de desarrollo con gaboxadol. CL2018000142A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (1)

Publication Number Publication Date
CL2018000142A1 true CL2018000142A1 (es) 2018-07-13

Family

ID=57774846

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000142A CL2018000142A1 (es) 2015-07-17 2018-01-17 Métodos para el tratamiento de trastornos de desarrollo con gaboxadol.

Country Status (16)

Country Link
US (8) US20170014393A1 (es)
EP (1) EP3324961A4 (es)
JP (3) JP2018520189A (es)
KR (1) KR20180031721A (es)
CN (2) CN108024997A (es)
AU (2) AU2016295138B2 (es)
BR (1) BR112018000933A2 (es)
CA (1) CA2992734A1 (es)
CL (1) CL2018000142A1 (es)
CO (1) CO2018000375A2 (es)
HK (1) HK1250951A1 (es)
IL (2) IL256912B2 (es)
MX (2) MX2018000745A (es)
PE (2) PE20230735A1 (es)
TW (2) TWI819995B (es)
WO (1) WO2017015049A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2875742T3 (es) 2014-06-06 2021-11-11 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del síndrome de Angelman
US20170014393A1 (en) 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US20180140586A1 (en) * 2016-11-22 2018-05-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
EP3648762A4 (en) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES
KR20210040358A (ko) 2018-06-14 2021-04-13 오비드 테라퓨틱스 인크. 안젤만 증후군의 치료에서 mir-92a 또는 mir-145의 사용
US20210177805A1 (en) * 2018-08-22 2021-06-17 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
KR20210062662A (ko) * 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
MX2021005994A (es) * 2018-11-21 2021-09-14 Certego Therapeutics Inc Combinacion de gaboxadol y litio para el tratamiento de trastornos psiquiatricos.
SG11202105358RA (en) 2018-11-21 2021-06-29 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
US20220226268A1 (en) * 2019-06-07 2022-07-21 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
CA3146737A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
JP2023507764A (ja) * 2019-12-18 2023-02-27 オービッド・セラピューティクス・インコーポレイテッド １ｐ３６欠失症候群の治療的処置のためのガボキサドール
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06011325A (es) * 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
EA200601853A1 (ru) * 2004-04-02 2007-02-27 Х. Лундбекк А/С Лечение нарушенной дыхательной функции
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EP1942879A1 (en) * 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2610508T3 (es) * 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US20140371210A1 (en) 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
CA2892811A1 (en) * 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
ES2875742T3 (es) 2014-06-06 2021-11-11 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del síndrome de Angelman
ES2664810T3 (es) 2014-06-12 2018-04-23 Pfizer Limited Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA
US20170014393A1 (en) 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
PE20181332A1 (es) 2015-08-11 2018-08-20 Ovid Therapeutics Inc Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
MX2022004734A (es) 2022-05-13
CN116531370A (zh) 2023-08-04
US20210030727A1 (en) 2021-02-04
IL256912B2 (en) 2024-01-01
EP3324961A1 (en) 2018-05-30
PE20230735A1 (es) 2023-05-03
CA2992734A1 (en) 2017-01-26
PE20190338A1 (es) 2019-03-07
AU2021250862B2 (en) 2023-11-09
US11096929B2 (en) 2021-08-24
AU2016295138A1 (en) 2018-02-08
AU2021250862A1 (en) 2021-11-04
HK1250951A1 (zh) 2019-01-18
KR20180031721A (ko) 2018-03-28
US20190117632A1 (en) 2019-04-25
JP2021130687A (ja) 2021-09-09
CO2018000375A2 (es) 2018-04-19
JP2023103375A (ja) 2023-07-26
US20180098974A1 (en) 2018-04-12
US20170014393A1 (en) 2017-01-19
IL305342A (en) 2023-10-01
TWI819995B (zh) 2023-11-01
TW201707700A (zh) 2017-03-01
TW202325293A (zh) 2023-07-01
WO2017015049A1 (en) 2017-01-26
EP3324961A4 (en) 2019-03-13
IL256912A (en) 2018-03-29
JP2018520189A (ja) 2018-07-26
US20180338960A1 (en) 2018-11-29
US20230071127A1 (en) 2023-03-09
BR112018000933A2 (pt) 2018-09-04
AU2016295138B2 (en) 2021-11-04
MX2018000745A (es) 2018-08-15
US20190321342A1 (en) 2019-10-24
US20190255027A1 (en) 2019-08-22
IL256912B1 (en) 2023-09-01
CN108024997A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
CL2018000142A1 (es) Métodos para el tratamiento de trastornos de desarrollo con gaboxadol.
UY36275A (es) Compuestos aminopirimidinilo
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2017001572A1 (es) Compuestos de triazolopirimidina y usos de los mismos.
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
CL2015000706A1 (es) Compuestos derivados biciclicos conteniendo nitrogeno y sus sales; su proceso de obtencion; composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de estados patologicos renales, hepaticos, inflamatorios, del sistema nervioso, enfermedades fibroticas y rechazo agudo y cronico del trasplante de organos.
ECSP17054980A (es) Inhibidores selectivos de bace1
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2015000787A1 (es) Derivados de 1,2,4-triazina para el tratamiento de infecciones virales.
CL2016002940A1 (es) Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112018001942A2 (pt) ?novo uso de sulfato de dextrano?
CO2019008110A2 (es) Activador de nrf2
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2016002532A1 (es) Compuestos derivados de diheterociclo enlazado a cicloalquilo con actividad inhibidora de gls1 uso en el tratamiento de crecimiento celular anormal, tal como cáncer composición farmacéutica que los contiene
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.